TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01291303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized ventilation
Description: Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ventilation
Description: Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available).
Study: NCT01045590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: titration
Description: Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: titration
Description: Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Study: NCT03619031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LONG LEAVENING
Description: a long-leavened (60 h) pizza composed of sourdough and a flour mix.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHORT LEAVENING
Description: a short-leavened (5 h) pizza composed of sourdough and a flour mix.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRADITIONAL
Description: a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
Study: NCT04917978

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematological Phenotype Analysis
Description: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio- Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).
Study: NCT00162123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Study: NCT03730103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same day discharge
Description: Patients will be discharged home from the hospital on the day of her surgery.
Study: NCT02626949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR Course
Description: Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEP Course
Description: HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
Study: NCT04105881

Intervention type: DIETARY_SUPPLEMENT
Intervention: Investigation
Description: Cross sectional intervention

Intervention type: DIETARY_SUPPLEMENT
Intervention: Investigation
Description: Cross sectional intervention

Intervention type: DIETARY_SUPPLEMENT
Intervention: Investigation
Description: Cross sectional intervention
Study: NCT00899964

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
Study: NCT04438057

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CCP
Description: Randomized open label study to receive 2:1 CCP to standard of care
Study: NCT01641445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate (200 mg daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capusules (sugar pills
Study: NCT03220919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-based
Description: Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose level-based
Description: Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, \>10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, \> 20 mmol/L.
Study: NCT01242865

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention and Interpretation Therapy
Description: Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book.
Study: NCT03010748

Intervention type: DEVICE
Intervention: Scheimpflug tomography system (Pentacam) measurement
Description: The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
Study: NCT04635618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Brief-Telepsychotherapy
Description: Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Telepsychotherapy
Description: Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychoeducation
Description: A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
Study: NCT02906709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin, 25 mg orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin, 25 mg orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to omarigliptin orally once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
Study: NCT00650936

Intervention type: DEVICE
Group type: OTHER
Intervention: AMPLATZER Septal Occluder
Description: AMPLATZER Septal Occluder
Study: NCT01545076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20 (low dose)
Description: 20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2% human albumin administered by weekly SC infusions during the SC treatment period of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: 10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: 10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IgPro10
Description: 10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20 (high dose)
Description: 20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)
Study: NCT04502342

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycloroquine and Azythromycine
Description: dual treatment with Hydroxycloroquine and Azythromycine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cospherunate/Azythromycine
Description: dual treatment with Cospherunate and Azythromycine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cospherunate/Phytomedicine/Azythromycien
Description: triple treatment with Cospherunate, Asen and Azythromycine
Study: NCT01030965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 125mcg
Description: 125mcg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 250mcg
Description: 250mcg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 500mcg
Description: 500mcg once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily
Study: NCT01584921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin (Epoetin-beta, NeoRecormon®)
Description: 5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin (Epoetin-beta, NeoRecormon®)
Description: 30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
Study: NCT00059371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: male circumcision

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: male circumcision
Study: NCT04978025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Silver
Description: Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
Study: NCT01124396

Intervention type: DRUG
Intervention: DSP-3025

Intervention type: DRUG
Intervention: Placebo
Study: NCT01417078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: single-dose; dosage in mg, based on patient body weight
Study: NCT00098371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Study: NCT03421860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with ephedrine
Description: measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with phenylephrine
Description: measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with ondansetron
Description: measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with nor-epinephrine
Description: measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Study: NCT03767192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: SPG stimulation and standard of care

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham SPG stimulation and standard of care
Study: NCT00098488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT02397733

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation (PCI)
Description: Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance PCI
Description: Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
Study: NCT04137211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with social break
Description: Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with walk break
Description: Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with simple resistance activities
Description: Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
Study: NCT02227121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation following induction of VT/VF
Description: Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
Study: NCT02282436

Intervention type: OTHER
Intervention: No specific intervention for this study
Description: No specific intervention for this study
Study: NCT02606565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: 4% chlorhexidine
Description: See previous description
Study: NCT03544138

Intervention type: DEVICE
Group type: OTHER
Intervention: Hummingbird Tympanostomy Tube System (H-TTS)
Description: The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
Study: NCT04365751

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous microwave ablation, Laparoscopic hepatectomy
Description: For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation, Laparoscopic hepatectomy
Description: For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
Study: NCT01056874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Oral Digoxin 0.25 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral Digoxin 0.25 mg single dose on Day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Oral Maraviroc 300 mg twice daily for 6 days
Study: NCT00359086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 given orally three times per week
Study: NCT00414401

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical Reminder